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1 
PREFACE 
 
In spite of its small size, FinOHTA is a strategic player in Finnish health care. 
During the first eight years of FinOHTA's existence, it has become a focal point of 
national health technology assessment activities. In the outcomes-oriented health 
care of today — with its strong emphasis on a sound evidence base — the 
importance of actors delivering reliable and relevant knowledge cannot be over-
estimated. To achieve its ambitious goals, the small unit has built strong networks 
with Finnish health care actors and within the international health technology 
assessment community. 
 
When STAKES was established as a new organization with a new mission in the 
early 1990's, it had to rapidly create new ways of operating. It was necessary to 
show a number of audiences that the new research and development 
organization could deliver unbiased, up-to-date knowledge that was relevant to 
developing Finland's health and social services. In relation to the clinical world, 
FinOHTA has been the showcase for STAKES. As the part of STAKES with the 
highest visibility in health care, FinOHTA has helped the whole organization to 
establish practical collaboration with health care actors. 
 
At the same time as the mother organization has gained from the work of 
FinOHTA, it has also worked the other way round. The largest health services 
research and health economics community in the country, STAKES, has created 
an environment conducive to health technology assessment. A national research 
organisation has been the ideal location from which to build up the critically 
important networks. Moreover, substantial synergies have been created by 
developing and sharing material and technical infrastructure that comes with a 
larger organisation. 
 
In many cases, organisational evaluations are quite normative, aiming at an 
objective assessment of the "goodness" of the organisation. Quite often, these 
evaluations include league tables of several organisations, which may also be 
used to direct the allocation of resources.  
 
The present evaluation of FinOHTA does not belong to the category of normative 
assessments. You couldn't even rank FinOHTA against other Finnish units since 
the role and work of FinOHTA is nationally unique. During the first years of its 
existence, the work of FinOHTA has been widely appreciated. There is a general 
consensus that the work of FinOHTA should be significantly strengthened. This 
has also materialized in the form of a high-level political decision, as the 
government has promised to more than triple the funding of FinOHTA in the next 
few years. 
 
The FinOHTA evaluation was expected to be development oriented, rather than 
normative. In other words, STAKES wants to ensure the maximum benefit from 
the new phase of development that has just started. It is a joint obligation of 
FinOHTA and the whole of STAKES to repay taxpayers by using the new 
resources as wisely as possible.  
 
A development-oriented evaluation of a health technology unit that operates in a 
complex context is not an easy task. To end up with long-sighted and feasible 
recommendations that are also practical enough to be implemented, you need to 
have a broad mix of expertise. In addition to understanding health technology 
assessment methodology and organisation, you need to understand health policy 
and health services as well as the clinical environment where the work is done 
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and where the results are utilised. When trying to locate leading experts from 
each of the fields mentioned above, we realised that people who could meet the 
requirements of the evaluation group membership are few and far between. We 
started ambitiously by asking the best experts we could envisage to carry out the 
exercise. As the commissioner of the evaluation, the STAKES senior management 
group was overjoyed when the composition of the expert group was confirmed. 
In fact, the group is a "dream team", embodying an impressive amount of 
expertise in a group of just five members. 
 
This preface is written before the final recommendations of the group are 
published. However, it is self-evident that the work of the evaluation group will 
have an impact. All suggestions will be meticulously contemplated. Any 
recommendation given will be implemented, unless an explicit, well-grounded 
decision not to do so is made. STAKES is committed to making maximum use of 
this valuable work. On behalf of the whole senior management group of STAKES, 
I express our warm gratitude to the whole evaluation group. Similarly, I reiterate 
the commitment of STAKES to developing FinOHTA to a new level of activity and 
impact. 
 
Helsinki, 6 August 2004 
 
 
Juha Teperi 
Deputy Director General (acting) 
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1 EXECUTIVE SUMMARY 
The Finnish health care sector is currently going through a reform process which 
is based on the Decision in Principle by the Council of State on securing the future 
of health care, published in 2002. The main goal of this reform is to ensure 
improved accessibility, timely availability, and high quality of health care services 
for the population. The health care system in Finland, like in other countries, must 
cope with increasing expectations and costs, as well as with regional variation in 
practices. Continuous quality improvement and reduction of gaps between 
research and practice are further challenges for the modern health care system. 
 
Internationally there has been a search for tools and methods to promote the 
effectiveness and efficiency of health care. Evidence-based medicine, systematic 
reviews, clinical practice guidelines and health technology assessment (HTA) are 
among the responses to these needs.  
 
The Finnish Office for Health Care Technology Assessment, FinOHTA, was set up 
in 1995 as part of the National Research and Development Centre for Welfare and 
Health, STAKES. FinOHTA has focused on micro-level assessment, i.e. on 
assessing individual health technologies. Other research groups within STAKES 
have been responsible for studying health services on the macro-level, focusing 
on organisational structures and systems.  
 
In the context of the national health care reform the Ministry of Social Affairs and 
Health has decided to increase the resources allocated to FinOHTA. The 
leadership of STAKES — foreseeing the possibilities in strengthening FinOHTA's 
role in the health sector — decided to carry out an external review of FinOHTA 
with the aim to optimize the use of increased resources. 
 
This report is based on the work of the international evaluation group chaired by 
Dr. Jarkko Eskola, retired Director General of the Ministry of Social Affairs and 
Health. The members of the group were Dr. Krister Höckerstedt (University of 
Helsinki), Dr. Hanna Mäkäräinen (Northern Ostrobothnia Hospital District), Dr. 
Andrew Oxman (Norwegian Health Services Research Centre, Norway), Dr. Nina 
Rehnqvist (Swedish Council on Technology Assessment in Health Care, Sweden). 
Dr. Kristian Lampe (FinOHTA) acted as the secretary of the group. 
 
The evaluation group approached its task in two ways. Firstly, through careful 
examination of detailed documentation of the FinOHTA's work during the past 
years. Secondly, by formulating a set of key questions that were used as a 
framework for extensive interviews. Some 16 experts representing various 
national organizations were interviewed using a structured interview scheme. 
Additionally, views of further 14 national and international experts were obtained 
through phone interviews or in writing. 
 
The evaluation group considered the background documentation and various 
aspects expressed in the interviews and — as a result of extensive internal 
discussions and analysis — concluded its work by collecting the main observations 
and practical recommendations in the closing chapter of this report.  
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The report presents 48 recommendations that address the mandate, scope and 
independence of FinOHTA. In the future, FinOHTA should continue developing 
and focusing its mission and position as the national coordinator, facilitator and 
expert in health technology assessment. The financiers and administrators should 
ensure that FinOHTA has an independent position that allows it to tackle 
assessment tasks that may be challenging both scientifically and from the 
viewpoint of health policy. The recommendations advocate FinOHTA's role as an 
independent advisor that bases its claims on scientific evidence, for the Ministry 
of Social Affairs and Health, for STAKES and for various other health care policy 
makers and service providers. Some of the recommendations confirm the hitherto 
practises and some propose the adoption of new roles and practices. An example 
of an issue that requires clarification in the future is FinOHTA's role in the 
assessment of pharmaceuticals. The evaluation group felt strongly that the roles of 
different organizations relevant to pharmacotherapy and its cost-effectiveness are 
not well defined and established, and that the mandates are not clear enough. 
Finally, the report also provides practical recommendations regarding the future 
recruitment of staff to meet the increased workload of FinOHTA.  
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2 BACKGROUND 
2.1 International Health Technology Assessment 
The Health Program of the Office of Technology Assessment (OTA), serving the 
U.S. Congress, initiated health Technology Assessment (HTA) as a formal process 
in the mid-1970's. However, a long history of concerns and developments 
preceded the formal establishment of HTA and has coincided with its further 
development. Concerns over variation in practice, the quality of health care, the 
cost of health care, and the ability to cope with the biomedical literature have 
contributed to the development of HTA and related developments. Evidence-
based medicine (EBM), systematic reviews, and clinical practice guidelines are 
among the developments that have occurred along side of HTA. A number of 
organisations have been created to support these developments, both within 
countries and internationally. These concerns and responses to them are not 
independent of each other and the boundaries between them are not always clear. 
2.1.1 What is HTA? 
Definitions of HTA vary along with what is included within the scope of HTA. The 
term HTA was first used in the United States Congress in about 1967, and the 
U.S. Congressional Office of Technology Assessment (OTA) was established in 
1972. The general definition of technology assessment used was: "a 
comprehensive form of policy research that examines the short- and long-term 
social consequences of the application or use of technology." 1  
 
HTA has subsequently been defined as "the systematic process by which the direct 
and indirect consequences of a particular technology are assessed; it is concerned 
with evaluating the safety, effectiveness and cost-effectiveness and (when 
appropriate) the social ethical and legal impact of a technology." 2  
 
More recently, the European Collaboration for Health Technology 
Assessment/Assessment of Health Interventions (ECHTA/ECAHI) project has 
described HTA as follows: 3  
 
Health technology assessment (HTA) seeks to inform health policy makers by using 
the best scientific evidence on the medical, social, economic, and ethical 
implications of investments in health care. Technology is broadly defined to include 
the drugs, devices, medical, and surgical procedures used in health care, as well as 
measures for prevention and rehabilitation of disease, and the organizational and 
support systems in which health care is provided.  
                                                 
1 Office of Technology Assessment. Development of medical technology: opportunities for assessment. Washington DC: U.S. Government 
Printing Office, 1976. 
2 Mosteller F, Falotico-Taylor J (eds). Quality of life and Technology Assessment. Washington DC: National Academy Press, 1989. 
3 Jonsson E, Banta HD, Henshall C, Sampietro-Colom L. Summary report of the ECHTA/ECAHI project. International Journal of Technology 
Assessment in Health Care 2002; 18:218–37. 
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Assessment includes: 
1. Identifying evidence, or lack of evidence, on the benefits and costs of health 
interventions; 
2. Synthesizing health research findings about the effectiveness of different health 
interventions; 
3. Evaluating the economic implications and analyzing cost and cost-effectiveness; 
and 
4. Appraising social and ethical implications of the diffusion and use of health 
technologies as well as their organizational implications. 
 
In its project on New and Emerging Health Related Technologies (NEHRT, part of 
OECD's Health Project, published 2004), OECD refers to HTA as a three steps 
process: 
 
1. Identification and prioritisation of research/ policy question 
2. Systematic review of the scientific evidence  
3. Appraisal of the evidence, including judgements about the meaning of the 
evidence, and views as to the values of a technology in the health care system. 
 
At a minimum, HTA addresses the efficacy of technologies; including health 
benefits, potential side-effects and comparisons of health benefits with 
alternatives. Frequently an economic evaluation, in the form of cost-effectiveness 
analysis is included. 
 
HTA, evidence-based health care (EBHC) and cost-effectiveness analysis (CEA) 
have been described as three interrelated concepts: "EBHC (the extension of 
evidence-based medicine to all health-care decisionmakers), CEA (a group of 
analytic tools bringing together costs and effectiveness) and HTA. HTA is the 
provision for health care decision-makers of high-quality research information on 
the cost, effectiveness and broader impact of health technologies; where health 
technologies are not just high-tech 'kit', but all interventions offered to patients. 
These three are not synonymous, but they are converging and they have 
common characteristics. These include a systematic approach to the evidence, a 
focus on patient-relevant outcomes, and the notion that policy decisions for one 
set of patients will affect others." 4 
 
"HTA is a broad concept with many facets and vague borders. It differs from 
country to country both in its foci and method. Probably a considerable part of 
the differences in HTA by country has depended on the interests of particular 
societal groups", including policy makers, insurers, clinicians, researchers, industry 
and the general public. 5  
HTA may include literature reviews alone, consensus processes with varying 
degrees of documentation, economic analyses, primary research, including 
randomised controlled trials (RCTs) and methodological research. Systematic 
reviews have come to be viewed as a core component of HTA, but the methods 
used in reviews can also vary widely and HTAs do not always include a 
systematic review. A systematic review is "a review of a clearly formulated 
question that uses systematic and explicit methods to identify, select and critically 
appraise relevant research, and to collect and analyse data from the studies that 
are included in the review. Statistical methods (meta-analysis) may or may not be 
used to analyse and summarise the results of the included studies." 6 
                                                 
4 Stevens A, Milnes R, Burls A. Health technology assessment: history and demand. Journal of Public Health Medicine 2003; 25:98–101. 
5 Banta D. The development of health technology assessment. Health Policy 2003; 63: 121–32. 
6 Alderson P, Green S, Higgins JPT (eds). Cochrane Reviewers’ Handbook Glossary 4.1.5 [updated December 2003]. In: The Cochrane 
Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd..  
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2.1.2 HTA agencies 
A total of 131 HTA organisations in 27 countries were identified in a directory 
that was published in 1998. 7 Today the numbers are probably higher. Some of 
these agencies are primarily engaged in primary research on health technologies, 
whereas many produce systematic reviews as a core activity with varying degrees 
of attention given to the applicability of the evidence in specific settings, 
economic analyses, and other context specific considerations such as 
organisational, ethical and legal implications. The international network of HTA 
agencies (INAHTA) consists of 42 agencies in 21 countries. To become a 
member of INAHTA an agency has to apply, be at least 50% funded by 
government and address HTA from a wide perspective.  
 
The 42 agencies in INAHTA vary greatly in terms of the number of permanent 
staff, funding, and operational procedures. All of them undertake or use 
systematic reviews and produce HTAs for varying ranges of health technologies. 
Some agencies are directly attached to government, others are departments 
within organisations under government, and others are independent 
organisations. Some are involved in policymaking or the production of clinical 
practice guidelines, some directly influence remuneration or legislation, and some 
inform policy decisions but are not involved directly in policymaking.  
 
Agency staff alone sometimes produce systematic reviews, agencies sometimes 
commission systematic reviews, and they sometimes produce reviews in 
collaboration with expert groups. Because the evidence included in systematic 
reviews is usually international and the same evidence is used in HTAs in different 
countries, there have been growing efforts to reduce unnecessary redundancy 
and improve the quality of systematic reviews used in HTAs through 
collaboration among HTA agencies and the use of systematic reviews produced 
by the Cochrane Collaboration. 8 INAHTA has agreed upon a checklist to use 
when producing systematic reviews in order to ensure quality. It has further been 
proposed that work should be started to try to harmonise the presentation of the 
scientific documentation used in HTAs so that the different agencies can better 
use each other's material when producing reports that are tailored to a specific 
context. 
 
Denmark, Finland, Norway and Sweden all have HTA agencies which are 
members of INAHTA: the Danish Centre for Evaluation and Health Technology 
Assessment (DACEHTA), the Danish Institute for Health Services Research (DSI), 
the Finnish Office for Health Care Technology Assessment (FinOHTA), the 
Norwegian Centre for Health Technology Assessment (SMM), the Swedish 
Council on Technology Assessment in Health Care (SBU), and (in Linköping, 
Sweden) the Centre for Medical Technology Assessment (CMT). FinOHTA has a 
good reputation in the international HTA community and collaborates closely 
with the other Nordic HTA agencies. Similarities and differences among four 
Nordic national HTA agencies are summarised in table 1. 
                                                 
7 Medical Technology & Practice Patterns Institute. Directory of Health Technology Assessment Organizations Worldwide 1998. 
http://www.mtppi.org/reports.php?repid=044&infotype=abstract  
8 The Cochrane Collaboration is an international organization that aims to help people make well-informed decisions about healthcare by 
preparing, maintaining and promoting the accessibility of systematic reviews of the effects of healthcare interventions 
(http://www.cochrane.org). 
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Agency Aims Organization Staff1 Budget2 
(€ per capita) 
Activities 
D
A
C
E
H
T
A
3
 
The key aim of DACEHTA is to implement the National Strategy for 
HTA - this includes carrying out health technology assessments (HTAs) 
and evaluations of public health services with the aim of improving 
quality, standards and value for money. It is also an objective to integrate 
HTA-principles into the running and planning of the public health service 
at all levels. The centre primarily targets health professionals and 
decision-makers at all levels as well as related research communities. 
National centre 
for HTA and a 
separate entity 
within the 
framework of the 
National Board of 
Health 
22 3.6 
(0,67) 
DACEHTA coordinates, initiates and produces broad and rapid HTA-reports 
based on systematic reviews. DACEHTA has an early warning activity. DACEHTA 
implements and gives financial support to a range of HTA activities in Denmark, 
including 3 local HTA units. DACEHTA produces clinical practice guidelines, and 
evaluates health service activities. Furthermore DACEHTA gives grants to local 
and regional HTA-project. 
F
i
n
O
H
T
A
4
 
To promote the use of proper evidence-based methods in the Finnish 
health care system in order to enhance the effectiveness and impact of 
health care. 
Department in the 
National Research 
and Development 
Centre for 
Welfare and 
Health (STAKES) 
13 1.5 
(0,29) 
FinOHTA co-ordinates HTA research, disseminates information and gives 
methodological and financial support to research projects. It provides both 
methodological and financial support to projects aiming at evaluating the clinical 
effectiveness or cost-effectiveness of a given health technology. Inasmuch as it is 
feasible, the projects should also investigate the social, ethical and legal aspects 
related to the technology. The Finnish branch of the Nordic Cochrane Centre is 
based within FinOHTA.5 
S
M
M
6
 
The main task of SMM is to critically review the scientific basis for 
methods used in health care and to evaluate their costs, risks and 
benefits. SMM is concerned with weeding out ineffective technologies, 
and ensuring that approved technologies are applied as efficiently as 
possible. Both new and established technologies are assessed. These 
include diagnostic and therapeutic procedures, medical devices and 
issues concerning the organisation of the health care system. 
Department in the 
Norwegian Health 
Services Research 
Centre 
24 1.7 
(0,38) 
SMM prepares full HTAs undertaken by expert groups together with SMM staff, 
limited HTAs, evaluation of international reports in the Norwegian context, 
evaluation of new technologies or new applications of old technologies, "early 
warnings", and response to queries based on available systematic reviews and 
HTA reports. SMM does not conduct or support primary research 
S
B
U
7
 
SBU has the mandate of the Swedish government to comprehensively 
assess healthcare technology from medical, economic, ethical, and social 
standpoints. SBU aims to compile impartial, scientifically based 
assessment reports to support decision-making in health care. Target 
groups include professional caregivers, healthcare administrators, 
planners and health policy makers. The findings also concern many 
patients and their families. 
Independent 
state-financed 
centre 
28 4.5 
(0,51) 
Teams consisting of experts from Sweden and abroad carry out full HTAs. In 
addition SBU prepares Alerts (early assessments concerning new technologies), 
has a network of 33 ambassadors throughout Sweden, and provides the 
secretariat for INAHTA. The ambassadors’ role is to initiate and participate in 
local and regional seminars and conferences, and to become locally known as 
opinion leaders for evidence-based medicine. SBU does not conduct or support 
primary research. 
Table 1. Comparison of some features of national HTA agencies in Nordic countries 
1. Permanent staff - approximate full-time equivalents. 
2. Budget for 2004 in millions of Euros. Population data from 2003, Statistics Finland World in Figures, http://www.stat.fi/tk/tp/maailmanumeroina/03_pinta-ala_vakiluku_ja_paakaupunki_maittain.xls  
3. Danish Centre for Evaluation and Health Technology Assessment (DACEHTA), http://www.sst.dk/Planlaegning_og_behandling/Medicinsk_teknologivurdering.aspx?lang=en 
4. Finnish Office of Health Technology Assessment (FinOHTA) http://www.stakes.fi/finohta/e/ 
5. More than a dozen Cochrane Centres around the world share responsibility for helping to co-ordinate and support members of the Cochrane Collaboration in areas such as training and support to reviewers and review 
groups to prepare, keep up-to-date and make accessible Cochrane reviews. Centres promote the objectives of the Collaboration at national level. A Cochrane Review is a systematic review of the benefits and risks of 
healthcare. Cochrane reviews are expected to adhere to guidelines published in the Cochrane Reviewers’ Handbook. The specific methods used in a Cochrane Review are described in the text of the Review. Cochrane 
Reviews adhere to a structured format that is described in the Cochrane Reviewers’ Handbook. 
6. The HTA, Reviews and Dissemination Department includes the former Norwegian Centre for Health Technology Assessment (SMM) http://www.kunnskapssenteret.no/smm/News/FramesetNews.htm and the former 
Knowledge Support Department of the Norwegian Directorate of Health and Social Affairs. The staff and budget is for the entire Department, of which the former SMM is about two thirds. 
7. The Swedish Council on Technology Assessment in Health Care (SBU) http://www.sbu.se/www/index.asp 
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2.2 FinOHTA until today 
2.2.1 History and task 
Several guidelines relevant to HTA were published already in 1979 by SITRA 
(Finnish National Fund for Research and Development). Some years later, the 
Academy of Finland published two reports on health care technology assessment 
in the second half of the 1980's. Also some other organisations made efforts to 
promote health care technology assessment in the 80's and early 90's. 
 
The Finnish Office for Health Care Technology Assessment, FinOHTA, was set up 
on the 1st of January 1995 within Stakes, the National Research and 
Development Centre for Welfare and Health. Stakes is subordinate to and 
financed by the Ministry of Health and Social affairs. FinOHTA was thus set up to 
be a publicly funded, national assessment agency. 
 
The tasks of Stakes are defined in the legislation 9,10. Although FinOHTA is not 
explicitly mentioned in the legislation, the task to evaluate and develop 
technology in the field of health (and social) care is assigned to Stakes, as well as 
the production and dissemination of information material. 
 
Some other groups and units within Stakes are also involved in research that is 
relevant to health technology assessment. Through internal division of labour, 
FinOHTA has had the main responsibility to assess individual health technologies 
or health conditions (micro-level assessment), whereas the other groups are 
mostly involved in studying health services on a more general level (health system 
research or macro-level assessment). Part of FinOHTA's projects have addressed 
organizational issues, too. 
2.2.2 Organization and staff 
Originally, and like some other units of Stakes, FinOHTA had a status of a "special 
unit" (erillisyksikkö in Finnish), which ensured a level of autonomy and the ability 
to define its own procedures for project approval and publication policies. In the 
general reorganization of Stakes in year 2000, FinOHTA was defined (as all other 
research units) as one of the "groups" within one of the larger divisions (i.e. the 
Health and Social Services Division). 
 
                                                 
9 Laki sosiaali- ja terveysalan tutkimus- ja kehittämiskeskuksesta 27.11.1992/1073. 
10 Asetus sosiaali- ja terveysalan tutkimus- ja kehittämiskeskuksesta 27.11.1992/1120. 
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Table 2. Organization chart of STAKES (since 2000) 
FinOHTA started as a small unit with only 3–5 employees over years 1995–1998. 
A considerable growth took place only after year 2002, as the number of full-time 
staff raised from 7 to the current 12. The growth of the recent years results mainly 
from hiring researchers and project managers to internal projects. 
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Table 3. Number of FinOHTA staff 
From early on, the activities were planned on strong networking with various 
relevant experts and organizations. The following structures were developed 
during the early years of FinOHTA to support the work of the Office. 
 
• Consultants 
Four senior consultants in medicine and biometrics provide regular and 
frequent support to the Office staff. 
• Scientific Committee 
The Scientific Committee promotes broad multidisciplinary expertise. It 
participates in the selection of assessment topics and ensures the 
commitment of different scientific fields to collaborative assessment work. 
The 9-member Committee is chaired by the head of FinOHTA. The 
Committee meets every 2–3 months. 
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• Advisory Board 
The Advisory Board represents various key interest groups and 
organizations of the society. It monitors and guides the operations of 
FinOHTA and promotes the dissemination and adoption of assessment 
results. The Board has 30 high-level members and is currently chaired by 
Dr. Jussi Huttunen, former head of the National Public Health Institute and 
current chief editor of the Duodecim Medical Journal. The Board convenes 
1–2 times per year. 
• Expert Network 
A network of some 60 national experts of various medical specialties and 
other health-related fields provide expert support for FinOHTA's staff and 
projects whenever needed. Recently the utilisation of the Network has 
been relatively low, with the exception of their involvement in the 
information dissemination activities. 
 
 
 
FinOHTA
Office
Permanent consultants
Expert network Scientific committee
Advisory board
STAKES
Director General
Management
STAKES
Health and Social Services Division
 
Table 4. Organization chart of FinOHTA 
It can be argued that until the year 2000, the leadership of FinOHTA was not on 
a solid basis. The official head of unit had applied for leave of absence and the 
position was filled during years 1996–1999 through a temporary arrangement. 
Two persons had the position of the acting head of unit (periods 1996–1998 and 
1998–1999). The leadership position was declared open as of the beginning of 
year 2000 and since then the leadership has been stabilized. The process caused 
some turmoil in the Office and as a result a considerable turnover in personnel 
took place in 2000 and 2001. As of year 2002, the staff structure has reached a 
new equilibrium and most employees have worked in the Office since 2002 or 
longer. (See Appendix 2) 
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2.2.3 Budget 
The budget of FinOHTA is defined within the Stakes budget. No clear 
"earmarking" of the resources available for FinOHTA exist. Until recently, the 
annual total budget of FinOHTA has been approximately 0.7 – 0.9 million euro, 
including both Stakes budget and external project funding (the amount of the 
latter has varied over the years between 5 and 15% of total budget). The budget 
has fluctuated primarily due to changes in Stakes total budget. 
 
As a result of the decisions that were made based on the National Health Project, 
the budget of FinOHTA for year 2004 is 1,08 million euro (excluding possible 
external project funding) and it will be increased up to the level of 2,5 million 
euro by the year 2007. The following figure displays the development of 
FinOHTA total budget over the years 2000–2004 (including external project 
funding). In these sums, the overhead cost is invisible. It amounts to an additional 
sum which is about 70% of the budget shown here and governed directly by 
FinOHTA. The overhead cost (that Stakes charges) covers the premises, 
administrative services, library and IT support, copying costs, etc.  
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Table 5. Total budget of FinOHTA 2000–2004. 
2.2.4 Brand 
Using its somewhat autonomous position within Stakes and drawing from the 
experience of international HTA agencies, FinOHTA has consciously developed 
its own brand and publications. The aim has been to make health technology 
assessment known among health care workers and decision-makers and to bring 
the results of assessments into everyday use. As lack of time is a common 
problem within health care, the use of easily identifiable materials has been 
regarded essential. 
 
The development of FinOHTA's own brand has been somewhat controversial 
within Stakes. In most cases, FinOHTA has been able to develop and use its own 
materials based on its needs and judgement. Sometimes, however, the need and 
appropriateness of such a policy has been criticized and questioned.  
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2.2.5 Activities of FinOHTA 
FinOHTA's activities can be divided into the following three categories: 
 
1. HTA research 
2. Dissemination of information 
3. National and international collaboration 
HTA research 
FinOHTA promotes HTA-related research in Finland by co-ordinating assessment 
activities, by launching its own assessment projects and by offering financial and 
methodological support to assessment projects conducted by external 
researchers. 
 
FinOHTA has construed HTA as a wide range of research activities. Although 
some international HTA agencies produce only (or mostly) systematic reviews of 
available evidence, FinOHTA has also been active in other types of research that 
might assist decision making in health care. Hence, there is no "typical" FinOHTA 
project. Instead, FinOHTA chooses a methodology that fits the research question 
at hand and consequently the projects can be divided into the following main 
categories: 
 
• Systematic reviews of available evidence 
• Primary studies (etc. randomized controlled trials) that study the 
effectiveness of cost-effectiveness of various health technologies (when 
there is no or not enough prior evidence available) 
• Surveys etc. (to clarify the use of technology or variation in practices) 
• Modelling the costs of various approaches to technology utilization 
• Development (e.g. when the technology assists further HTA information 
retrieval) 
 
Since 1995, a total of 60 research projects have been completed. Currently 
FinOHTA participates in 27 projects. More information on the topics and statistics 
of FinOHTA projects is available as Appendix 4. 
Dissemination of information 
In addition to supporting and conducting HTA research in Finland, FinOHTA acts 
as a clearinghouse for information on health technology assessment. Guidance 
through information provision is FinOHTA's fundamental method for influencing 
the health care system. FinOHTA actively acquires information from national and 
international sources. The information is tailored according to local needs and 
disseminated to the health care actors, decision makers, and the general public. 
 
The potential clientele of FinOHTA is very broad. In principle it encompasses 
everyone who operates within health care or whose work is in some way related 
to health care, as well as the general public (i.e. patients or consumers). During 
the early years of FinOHTA, the emphasis of communications was consciously 
and intentionally placed on interaction with clinical decision makers (primarily 
physicians). Due to public availability of information through the Internet, 
however, also the general public has had access to the information from early on. 
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Also the national media (TV, radio, newspapers, etc.) has adopted FinOHTA as an 
information source, both in the context of FinOHTA's own projects, and as a 
provider of background information in various topics. Since FinOHTA operates 
under the auspices of the Ministry of Social Affairs and Health, the Ministry is an 
obvious and central client. Likewise, other government organizations (e.g. the 
National Public Health Institute or The Institute of Occupational Health) are 
important partners. 
 
FinOHTA has used (and mostly still uses) the following methods and media to 
disseminate information: 
 
• Own publications 
- Newsletter Impakti (6 issues per year) 
- FinOHTA Reports (results of own research projects) 
- Technology Updates (translations of the results of foreign projects, 15 
issues during 1995–2000) 
- Brochures of FinOHTA 
• Targeted communication (notifications of foreign HTA results to national 
experts) 
• World Wide Web (Site online since 1995, over 600 000 page requests in 
2003) 
• Project communications (to address specific needs of each project) 
• Replies to information requests (from various organizations and individuals) 
• Library collection of approximately 1000 items (mostly international HTA 
reports) available for public use 
• Education (courses, seminars) 
• Utilization of other media 
- Physician's CD (CD ROM with practice guidelines and a large variety of 
other material) 
- Terveysportti (web site) 
- Finnish Medical Journal (professional and scientific journal) 
- Kuluttajauutiset (monthly newspaper on consumer issues) 
- Duodecim 
National and international collaboration 
An extensive and intensive national and international collaboration network has 
been and is the fundamental base for FinOHTA's operations. Various forms of 
collaboration include e.g. research cooperation and coordination, information 
exchange and dissemination, and educational activities. 
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Until now, FinOHTA has collaborated primarily with the following organizations 
and bodies: 
 
National level 
 
• Hospital districts 
• Ministry of Social Affairs and Health11 
• Universities 
• Finnish Medical Society Duodecim12 
• Current Care project13 
• Primary health care centers 
• Other research groups of Stakes 
• National Public Health Institute14 
• Occupational Health Institute15 
• National Agency for Medicines16 
• ROHTO17 
 
International level 
 
• INAHTA, the International Network of Agencies for Health Technology 
Assessment18 
• HTAi, Health Technology Assessment International19 
(formerly ISTAHC, the International Society for Technology Assessment in 
Health Care) 
• NOHTA, Nordic collaboration of national HTA agencies 
• Cochrane Collaboration20 
• AGREE, Appraisal of Guidelines Research and Evaluation21 
• GIN, Guidelines International Network22 
                                                 
11 http://www.stm.fi 
12 http://www.duodecim.fi 
13 http://www.kaypahoito.fi 
14 http://www.ktl.fi 
15 http://www.ttl.fi 
16 http://www.nam.fi 
17 http://www.rohto.fi 
18 http://www.inahta.org 
19 http://www.htai.org 
20 http://www.cochrane.org 
21 http://www.agreecollaboration.org 
22 http://www.g-i-n.net 
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2.3 Future expectations 
According to many independent observations and observers, Finnish health care 
is effective, efficient and remarkably equitable, especially from the point of view 
of equity in provision. The financing of care still contains a number of unusual 
features that undermine an otherwise equitable system. 23 The basic design 
ensures that health care services are principally under the control of local 
populations. Nonetheless, the Finnish health care system, like other health are 
systems, must cope with increasing expectations and costs, variation in practice, 
the need for continuous quality improvement, and reducing gaps between 
research evidence and practice. 
 
In response to these needs, there is growing demand for evidence-based health 
care and political solutions. The State Council announced the package of health 
sector reform proposals in April 2002 as a part of the country’s "national project" 
with the aim to ensure the availability and quality of the health care services. 
Some of these proposals have already been implemented including increased 
funding for the evaluation of health care technology. 
 
Health technology assessment including pharmacoeconomic assessment will and 
should play an increasing role in Finland. It is also important to recognise that 
HTA can inform decision-making but it is not a substitute for it. Values, culture, 
ethics, psychology and politics complicate the equation.  
 
Assessments can be used to support decision making at the micro (clinical), meso 
(hospital or health authority) and macro (government, insurance) levels. 
Government and health care organizations will increasingly require 
pharmacoeconomic assessments of the costs and benefits of new drugs. 
Assessments will and should be used in the development of evidence-based 
clinical practice guidelines, e.g. Current Care -guidelines.  
 
The role of HTA will be valuable because many widely used technologies are of 
uncertain effect in terms of improving patient/population health. Further, there is 
a need to improve the interaction between producers and users of HTA. For 
instance in Canada, to improve the use of HTA in decision-making Ontario Health 
Technology Advisory Committee was established to bring together senior hospital 
decision-makers and clinical experts to identify new and emerging technologies 
and set priorities for assessment. The committee promotes the use of HTA in 
decision making by bridging the worlds of evidence and decision-making.24 
 
Since the introduction of HTA in the seventies, many challenges remain, including 
future technologies. Over the next 20 years biotechnology will take health 
beyond the traditional treatment concepts of palliation, cure and prevention. 
Such new technologies will have important economic and bioethical 
consequences.  
 
                                                 
23 Health Care Systems in Transition; Finland, written by Jutta Järvelin and edited by Ana Rico and Teresa Cetani. European Observatory on 
Health Care Systems (2002), Vol. 4, No 1. 
24 Towards High-Performing Health Systems. The OECD Health Project. ISBN 92-64-01555-8, OECD 2004. 
The Future of FinOHTA — an External Review 
 
 
 
 
 
 
 
20 
3 REVIEW PROCESS 
3.1 Mandate and aim 
The Ministry of Social Affairs and Health has decided to increase the resources 
allocated for FinOHTA during the next years. In order to ensure optimal use of 
the increased resources, the leadership of Stakes decided to invite an 
international expert group to support the development of FinOHTA.  
 
As the aim of the process is to support optimal future development of FinOHTA, 
the evaluation group decided to focus on  
1) charting various expectations that relevant parties have of the functions and 
services of a national technology assessment organization,  
2) considering these expectations in the light of experience gained in an 
international (mainly European) context, and  
3) formulating recommendations for the future development. 
 
Thus, the main angle of view of this review is towards the future. 
3.2 Process 
The evaluation commenced in the beginning of the year 2004. The international 
evaluation group convened in Helsinki three times (in February, May and June). 
 
The group heard a broad spectrum of experts (representing relevant 
organizations) during the meetings. 
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Table 6. Organizations and persons who were interviewed 
 
Organization 
 
Representative(s) 
 
Association of Finnish Local and Regional Authorities 
 
Liisa-Maria Voipio-Pulkki 
Administrative Chief Physician 
Cancer Society of Finland Harri Vertio 
Secretary General 
(former executive director of the Finnish Centre for Health Promotion) 
Finnish Medical Society Duodecim Juha-Pekka Turunen 
Head of Education 
FinOHTA Head, professor Marjukka Mäkelä 
Various staff members 
FinOHTA Martti Kekomäki 
Professor, University of Helsinki 
Permanent Consultant 
Risto Roine 
Chief Physician, Helsinki and Uusimaa Hospital District 
Permanent Consultant 
Olli-Pekka Ryynänen 
Secretary General, Finnish Lung Health Association 
Permanent Consultant 
Ministry of Social Affairs and Health Risto Pomoell 
Ministerial Counsellor, Health Affairs 
Päivi Hämäläinen 
former Project Manager of the National Health Project 
National Agency for Medicines Erkki Palva 
Professor, Head of Deparment 
National Authority of Medico-Legal Affairs Antero Mäkelä 
Chief Physician 
National Occupational Health Institute Hilkka Riihimäki 
Head of Department 
National Public Health Institute Pekka Puska 
Director General 
National Social Insurance Institution Jorma Järvisalo 
Deputy Head of Research Department 
ROHTO (National Development Centre for 
Pharmaceutical Treatment) 
Arja Helin-Salmivaara 
Development Manager 
STAKES Management Vappu Taipale 
Professor, Director General 
Juha Teperi 
Deputy Director General (acting) 
STAKES Health and Social Services Division Ilmo Keskimäki 
Director of Division (acting) 
STAKES FinSOC (Finnish Evaluation of Social Services) Riitta Haverinen 
Group Manager 
STAKES CHESS Markku Pekurinen 
Head of Chess 
Hospital Districts Timo Keistinen 
Vaasa Hospital District, VSHP 
Antero Kesäniemi 
Northern Ostrobothnia Hospital District, PPSHP 
Anja Tuulonen 
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Northern Ostrobothnia Hospital District, PPSHP 
Taina Turpeenniemi-Hujanen 
Northern Ostrobothnia Hospital District, PPSHP 
Jorma Penttinen 
Hospital District of Northern Savo, PSSHP 
Jukka Puolakka 
Central Finland Health Care District, KSSHP 
Hannu Puolijoki 
Southern Ostrobothnia Hospital District, EPSHP 
Eva Salomaa 
Lapland Hospital District, LSHP 
Olli Wanne 
Satakunta Hospital District, SATSHP 
International Network of Agencies for Health 
Technology Assessment INAHTA (Finn-Boerlum 
Kristensen, Berit Moerland) 
Finn Boerlum Kristensen 
Chairman 
Berit Moerland 
Ex-Officio 
WHO HEN (Egon Jonsson) Egon Jonsson 
HEN Team Leader 
Private individuals Marjatta Blanco 
retired deputy director general, Department of Health, Ministry of Social Affairs and 
Health 
Jussi Huttunen 
Reporting Adviser of the Science and Technology Policy Council of Finland 
Chairman of FinOHTA's Advisory Board 
former Director General of the National Public Health Institute 
 
 
Most parties were heard during group interviews that were arranged in May at 
Stakes. The National Public Health Institute and the hospital district directors 
provided their feedback through email communication. Representatives of 
INAHTA and WHO HEN were interviewed by telephone or personal contact. 
 
The evaluation group agreed on ten key questions during its first meeting and 
used these in the interviews. The discussions, however, were not limited to the 
topics presented in the questions. 
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Table 7. Evaluation Questions 
Purpose 
 
1. What are the ideal aim/mission and practical goals for FinOHTA? 
 
2. What should be FinOHTA's main target audience(s)? Is there currently too strong an emphasis on 
reaching physicians? 
 
3. How should FinOHTA choose topics for assessment? What kinds of questions should be 
answered? 
 
4. How should FinOHTA relate to pharmaceuticals within the Finnish health care system? 
 
Position 
 
5. Should FinOHTA be more independent? Who should define priorities in research topics and 
methods? 
 
6. What is the role of FinOHTA in national and international collaboration? 
 
7. Should FinOHTA have local "satellites" in Finland, to what extent decentralise activities? 
 
Action 
 
8. Should FinOHTA fund external research? If so, to what extent and what kind of research? 
 
9. What should FinOHTA's role be in the implementation of HTA results? 
 
Quality 
 
10. How to ensure FinOHTA's internal competence in various fields and access to external 
competence whenever needed? 
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4 REFLECTIONS AND RECOMMENDATIONS 
After listening to the relevant parties and reviewing available background 
documentation, the Evaluation Group considered the various views that were 
expressed and formulated its conclusions and recommendations in response to 
the 10 questions that were posed as well as additional issues that were raised in 
relationship to these questions. The main observations and recommendations are 
presented in this chapter. Some of them support and confirm FinOHTA's hitherto 
practices and some suggest a change and the adoption of new practices.  
The key recommendations are numbered sequentially and marked with  
a vertical bar. 
4.1 Aim and mission 
(1) FinOHTA needs a clear and compelling aim for its activities. The focus of 
the activities should be on the provision and dissemination of evidence on 
the effectiveness and cost-effectiveness of health technologies, as well as 
on the support for HTA and evidence-based health care in Finland. 
 
HTA does not have a precise definition and its scope varies from country to 
country. Its core components include systematic reviews, particularly of evidence 
of the effects of health technologies – which is international – and "health 
technology assessments" which are context specific and may include economic 
analyses and assessments of needs, resources, ethical considerations.  
 
(2) Although primary research, including randomised trials and methodological 
research, is sometimes included within the scope of "HTA", these should 
not be considered core activities of FinOHTA.  
 
(3) FinOHTA should be more active in initiating projects studying issues that 
are important to health care decision making in Finland.  
 
Evidence from effectiveness research should be considered taking into account 
local information on needs, resources and costs. Hence, the information should 
be tailored to the local context. In this process, the benefits, harms, and costs of 
technologies should be considered. Values or preferences also need to be taken 
into account when making decisions or recommendations. Although FinOHTA 
does not make recommendations, it can help to clarify the role and potential 
impact of different values that might be used in balancing benefits against harms 
and costs. 
 
All products of FinOHTA should be of high quality.  
 
(4) Processes to ensure the quality should continue to be developed.  
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(5) FinOHTA should not make recommendations or take primary responsibility 
for the implementation of recommendations. A clear strategy with regard to 
responsibilities for translating the results of HTAs into recommendations 
and implementing those recommendations is needed, both within 
FinOHTA and more widely among the various organizations in Finland that 
share responsibility for this. 
 
Currently, the role of FinOHTA in relation to other relevant health care 
organizations involved in knowledge production and dissemination is not clear 
enough. For example, the role of FinOHTA in producing assessments regarding 
pharmaceuticals is not clear in relation to Rohto and other organizations (e.g. the 
Pharmaceutical Pricing Committee, the National Agency of Medicines and the 
National Social Insurance Institution).  
 
(6) The role of FinOHTA should be clarified, particularly in relationship to 
pharmaceuticals and clinical practice guidelines (e.g. Current Care project 
and the Evidence-based Guidelines). 
 
(7) FinOHTA should have a role in education, particularly in training related to 
evidence-based health care. For example, PhD candidates can contribute to 
HTAs as part of their thesis. Generally FinOHTA should not have primary 
responsibility for education, but should support universities and others with 
this mandate. 
4.2 Organizational Issues 
(8) The Advisory Board of FinOHTA should have a more active role, 
particularly in issues of strategic importance. Reducing the size of the 
Board, reconsidering its composition, and having it convene more often 
than twice a year could help to accomplish this. More active involvement 
of the Board will provide FinOHTA with a more stable and active contact 
with important actors in the field of healthcare. Alternatively, a sub-group of 
the Board could have a more active role. The composition of the Board 
should also be reconsidered to ensure that its members have enough time 
and interest to participate actively. The members of the Board should have 
an appropriate mandate from their organizations. 
 
(9) The Scientific Board should have a clearer decision-making role in 
prioritizing HTA projects. Someone outside of FinOHTA should chair the 
Board. This would help ensure open discussions as well as full participation 
of the head of FinOHTA, who should be a full member of the Board. 
 
(10) The Report Series of FinOHTA should have an Editorial Board with 
members outside Stakes. It should be considered whether the Scientific 
Board could also act as the Editorial Board. 
 
(11) Since FinOHTA is not yet very well known within Finland, interventions 
should be aimed at making it more known on the national level. 
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(12) On national level, it would be useful to clarify roles of various organizations 
that are relevant to evidence-based healthcare. As mentioned earlier, such 
clarification would be particularly important in relationship to 
pharmaceuticals. Similar clarification would be important particularly in 
relation to the Current Care project. A comprehensive mapping of the roles 
and activities of all of the relevant organizations would be useful. 
 
Some of us and also of those we interviewed raised the issue of the name of 
FinOHTA. 
 
(13) Consideration should be given to finding a Finnish name and acronym. 
FinOHTA could still be used in English. 
4.3 Independence and priority setting 
One of the key factors for the success of a HTA organization is that it is perceived 
to be independent and of high intellectual integrity.  
 
Those we interviewed expressed various perceptions regarding where and how 
FinOHTA should be organised.  
 
(14) Currently it seems to be that FinOHTA should continue being situated 
within Stakes, provided that an independent position within the 
organization can be guaranteed. 
 
In this context, an independent position includes the following: a) intellectual 
integrity and scientific independence, b) financial independence and c) the ability 
to maintain its own publications and brand. 
 
Intellectual integrity and scientific independence includes the ability to 
independently select assessment methods, draw conclusions and publish results 
using its own editorial process. Furthermore, although FinOHTA is financially 
dependent on the Ministry of Social Affairs and Health, it should be independent 
from the Ministry in selecting methods it uses, interpretations and publishing of 
the results. As an organization, FinOHTA should be able to express views (based 
on evidence) that are not in accordance with the Ministry's current view. 
 
FinOHTA assists the Ministry directly by providing answers to questions that have 
been posed by the Ministry.  
 
(15) Any such questions and answers should be made public. 
 
Financial independence refers to FinOHTA's ability to control its budget.  
 
(16) FinOHTA should have an "earmarked" budget within Stakes budget, i.e. 
have its own "line" within Stakes’ budget. 
 
FinOHTA is not yet well known within the field of health care.  
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(17) FinOHTA should continue efforts to make its "brand" and products known, 
particularly since some actors in the field of health care regard Stakes 
primarily as an organization active in the social care sector. 
4.4 Target audience 
Health care decision makers and other policy makers on all levels should be the 
main target audience of FinOHTA. The public health care sector should be the 
main audience, but the private sector should also be taken into account 
whenever appropriate. 
 
(18) The primary target of FinOHTA should be organizations responsible for 
making health policy and clinical practice guidelines, as well as 
organizations that are responsible for providing health care services - not 
individual clinicians.  
 
Physicians are key decision makers on the clinical level. FinOHTA should also 
target other professionals and consumers. Furthermore, FinOHTA should increase 
awareness among the public of the results of HTA and how the results are 
derived. 
4.5 Assessment topics 
(19) Assessment topics should be selected using explicit criteria and a 
transparent selection process. The criteria list should include criteria for 
priority setting.  
 
The list should address the following aspects: 
 
• how common the problem is 
• how severe the problem is 
• how costly it is 
• the extent of variation in practice 
• the extent to which practice may not be in accordance with existing 
evidence 
• the extent of uncertainty regarding what evidence there is 
• the extent of uncertainty regarding how the evidence should be applied in 
Finnish context 
 
The Scientific Committee currently provides advice on priority setting, although 
they may not be in the best position to do that from a societal viewpoint. This is 
somewhat problematic.  
 
(20) Consideration should be given to involving the Advisory Board in decisions 
regarding large HTA projects. 
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4.6 Pharmaceuticals 
Assessment of pharmaceutical therapies is important in Finland and other 
countries, both economically and from the viewpoint of patient safety. It is a 
problematic area because there are several organizations with overlapping 
responsibilities and some gaps in responsibility.  
 
(21) The Ministry of Social Affairs and Health should take initiative to have a 
common discussion with FinOHTA and other relevant organizations, 
primarily the National Agency of Medicines and Rohto, to clarify their 
respective roles and responsibilities. 
 
An additional problem is that there is limited capacity to undertake systematic 
reviews and economic analyses in Finland and internationally. Consequently, 
 
(22) Formal international collaboration in the field of pharmaceuticals should be 
encouraged. This might initially build upon existing Nordic collaboration. 
Nationally, the limited resources should be coordinated to ensure optimal 
use of the available capacity.  
 
If FinOHTA does not consider pharmaceuticals, it would be unable to look into 
issues from a broad perspective. Consequently, 
 
(23) FinOHTA should take responsibility for assessing different treatment 
options, including pharmaceuticals. This is particularly important in the 
context of assessments of the cost-effectiveness of alternative treatment 
options for a health problem. To the extent that FinOHTA assesses 
pharmaceuticals, it needs to ensure that it has expertise in clinical 
pharmacology. 
 
Unless a decision is taken together with the Ministry and other relevant 
organizations to have a clear division of labour and responsibilities in which 
FinOHTA does not have any responsibility for assessing pharmaceuticals,  
 
(24) FinOHTA should not exclude technology assessments of pharmaceuticals. 
 
FinOHTA should not accept funding from pharmaceutical industry. 
 
One possible solution to clarifying the current situation would be to reconsider 
the organization of FinOHTA and Rohto (e.g. to merge the two units). It may also 
be appropriate to reconsider the role and position of Current Care project. This 
can be arranged through a formal agreement between FinOHTA and Current Care. 
 
Until this is resolved, recent plans of FinOHTA to hire a shared economist 
together with the Rohto, should be reconsidered. FinOHTA should consider 
whether this is an appropriate arrangement. 
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4.7 International collaboration 
International collaboration is an integral part of FinOHTA's activities.  
 
(25) FinOHTA should continue being active in the international HTA field, 
particularly by collaborating with the International Network of Agencies for 
Health Technology Assessment (INAHTA) and the Health Technology 
Assessment International (HTAi). 
 
Currently the head of Unit has been responsible for most international tasks. 
More people should be involved in such tasks in the future. 
 
FinOHTA should also continue being active in the Cochrane Collaboration.  
 
(26) The Finnish branch of the Nordic Cochrane Centre should continue being 
located in FinOHTA. 
4.8 Decentralized activities 
Preliminary plans of creating local satellite offices for FinOHTA in some major 
cities have been discussed. In the near future, however,  
 
(27) FinOHTA should not have such local offices, since it is important to ensure 
a critical mass with diverse competency in a central location, and because 
additional offices would require considerable resources. 
 
For practical reasons, however, it might be feasible, to make arrangements for 
more permanent remote work possibilities. Such arrangements are up to 
FinOHTA to decide, based on current needs.  
 
Collaboration and networking on national level is very important.  
 
(28) FinOHTA needs to identify people in various locations in Finland who can 
be engaged in HTA processes (projects, information dissemination, etc.). 
Local contact persons might assist in designing projects prior to sending 
them to FinOHTA for consideration. 
4.9 Funding of external research 
(29) It is appropriate for FinOHTA to fund systematic reviews and economic 
analysis. 
 
With respect to supporting primary research, the policy requires some refinement 
according to the following principle:  
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(30) If a topic that requires clarification through a primary study is identified 
within a technology assessment, FinOHTA could provide methodological or 
limited financial support for protocol development and pilot studies for a 
primary research project rather than acting as a research funding agency for 
primary studies.  
 
It may be important to provide methodological support to research groups so 
that the studies will more easily get external funding elsewhere. 
 
(31) One mechanism for doing this, as well as building capacity in Finland, 
would be to fund visiting professors or scientists to work at FinOHTA. 
 
(32) FinOHTA should also support implementation research. 
 
(33) The Ministry of Social Affairs and Health should consider acknowledging 
the scientific merit of FinOHTA reports, for example through awarding 
"EVO points" to the host organizations of contributing authors. 
4.10 Implementation 
Health technology assessments provide information that should be used in policy 
decisions and clinical practice guidelines.  
 
(34) FinOHTA should play a role in ensuring that information from assessments 
is used, but it should not be the primary body responsible for 
implementation. 
 
(35) FinOHTA should provide support for implementation organizations (such 
as hospital districts, health care centres, medical schools, and medical and 
health organizations) on the local level and relevant projects (such as 
Current Care). The support should include providing information about 
implementation strategies, advice, training and help with evaluations of 
implementation strategies. 
 
(36) There is a need to clarify the roles and co-ordination of various 
organizations that are involved in dissemination and implementation 
activities. There is a need for a national strategy on this issue, perhaps even 
for a new structure. Implementation strategies should be evidence-based 
and a national strategy should include mechanisms to help ensure that they 
are. 
 
(37) FinOHTA should also provide support to medical schools in implementing 
evidence-based healthcare. In this process, it would be useful to have HTA-
related academic positions (e.g. professors) in medical schools. 
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4.11 Internal and external competence 
Securing both the internal and external competence of FinOHTA requires 
multiple measures. Visiting professors could provide contact points to research 
being undertaken in various organizations.  
 
(38) As cost-effectiveness studies are an important component of FinOHTA's 
work, more economic expertise is needed.  
 
(39) FinOHTA should ensure that its staff has an adequate amount of internal 
education and that the staff have opportunities to visit other organizations 
to enhance their scientific skills.  
 
(40) Special emphasis should be placed on ensuring the stability of the 
personnel. (See Appendix 2) 
 
(41) FinOHTA should develop and use systematic self-assessment of its 
processes, projects and products. 
 
It is important for FinOHTA to keep a high profile and to be recognized for 
scientific competence.  
 
(42) FinOHTA should work toward a situation where participation in its projects 
is also regarded as having academic merit. For example, systematic reviews 
should be recognised as part of PhD theses. 
 
(43) In addition to assessment projects, FinOHTA should also be active in 
research that is relevant to technology assessment. Such areas include 
implementation research and methodology research. 
4.12 Use of additional resources 
The number of FinOHTA staff will increase during the following years. A large 
unit, however, requires a different organizational structure than a unit that is of a 
reasonable size. To prevent the need for major organizational changes,  
 
(44) FinOHTA should limit the size of its staff. An appropriate number would be 
between 20 and 24. Additional resources should be used for external work. 
 
The following rule of thumb could be used in this process:  
 
(45) Less than 50% of the final 2.5 million euro should be used on staff 
expenses, and the rest should be used for other purposes. 
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(46) The following competencies should be ensured: 
 
–methodological (HTA) and statistical competence 
–medical and pharmacological competence 
–health economic skills 
–information science skills 
–communication skills 
–service functions (support staff) 
 
Considering the current division of the staff expertise and the expansion of the 
staff,  
 
(47) there is a clear need to increase competence in the following areas: 
information science, communication, health economics, statistics and 
clinical pharmacology.  
 
(48) The core activities of FinOHTA in the future should be health technology 
assessments, including: 
 
–systematic reviews 
–economic analyses 
–application of evidence to the Finnish context (including assessments of 
needs, resources, organizational, ethical and legal consequences) 
–horizon scanning 
–monitoring, adaptation and dissemination of the findings of international 
HTAs 
–providing rapid responses to questions raised by the Ministry of Social 
Affairs and Health. 
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5 APPENDICES 
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Appendix 1: Abbreviations 
Some common abbreviations and acronyms used in the context of health 
technology assessment are explained in the following table: 
 
Abbreviation 
 
Explanation 
 
AGREE 
 
 
Appraisal of Guidelines Research and Evaluation (Organization) 
 
CEA 
 
 
Cost-effectiveness analysis 
 
Current Care 
 
 
A Finnish project that develops clinical practice guidelines 
 
EBM 
 
 
Evidence-based medicine 
 
EBHC 
 
 
Evidence-based health care 
 
ECHTA 
 
 
European Collaboration for Health Technology Assessment 
(Organization) 
 
ECAHI 
 
 
European Collaboration for Assessment of Health Interventions 
(Organization) 
 
GIN 
 
 
Guidelines International Network (Organization) 
 
HTA 
 
 
Health Technology Assessment, sometimes also Health Care Technology 
Assessment 
 
HTAi 
 
 
Health Technology Assessment International (Organization) 
 
INAHTA 
 
 
International Network of Agencies for Health Technology Assessment 
(Organization) 
 
NOHTA 
 
 
Nordic collaboration of national HTA agencies (Organization) 
 
RCT 
 
 
Randomized Controlled Trial 
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Appendix 2: FinOHTA staff over time 
The following figure is a graphic representation of FinOHTA's staff members over time. Black vertical bars represent change of person holding a position. 
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Appendix 3: FinOHTA projects 
This document lists all ongoing FinOHTA projects and most of the already 
completed projects. All ongoing projects are marked with an asterisk (*). An 
analysis of the number and types of projects launched and completed during the 
years 1999–2004(June) follows the projects. Finally, a draft of renewed project 
criteria is presented. 
Internal projects 
The following projects have been carried out primarily by FinOHTA staff. Also 
external projects (i.e. projects that have been realized by external researchers) 
have been included, if the results have been published as FinOHTA Reports and 
consequently the Office has had a major role in preparing the report. 
 
1. * Mikstra Programme (Antimicrobial Treatment Strategies), 1998–2006 
2. * Effectiveness of helicopter use in emergency medical services, 1999–
2001 (completed), 2003–2004 (continuation project) 
3. * Blood glucose self-monitoring in diabetes, 2002–2004 
4. * Elevated blood pressure, 2002–2004 
5. * Rehabilitation of Cerebral Palsy, 2003–2005 
6. * Effectiveness of preventive home visits in community-dwelling elderly, 
2003–04 
7. * Prenatal screening of foetal anomalies in Finland, 2004  
8. * Glaucoma screening, 2003–2004 
9. * Effectiveness of interventions for coronary heart disease, 2004 
10. * Endoscopic sympatectomy, 2002–04 
11. * Prioritization of clinical guideline topics, 2003–2004 
12. Newborn screening in Finland, 2002–2004 
13. Guidelines for health care unit costs in Finland, 2001–2002 
14. Annual costs of medical technology in hospitals, 1998–99 
15. Assessment of an electronic referral and teleconsultation system between 
secondary and primary health care, 1998–99 
16. Assessment of the Satakunta Macro Pilot Project, 1999–2002 
17. Breast cancer screening among women aged 60–69 years, 2000 
18. Colorectal cancer screening, 2000 
19. From traditional film-based radiology to digital imaging, 1999–2001 
20. Coronary angioplasty in Finland - An overview of the situation in 2000 and 
an estimation of needs in the near future, 2000–2001 
21. Treatment of pain caused by endometriosis, 2001 
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Currently active external projects 
The following projects are carried out mainly by researchers working in various 
organizations (outside FinOHTA). FinOHTA provides methodological and 
financial support for the projects. The results are published mostly as scientific 
articles. Completed external projects are not included in the list. 
 
22. * Regional variation in the treatment and treatment results of congenital 
malformations requiring urgent surgical treatment 
23. * Effects of cardiac rehabilitation: psychosocial change, use of health care 
services and cost-effectiveness  
24. * Effectiveness of corset in low back pain during pregnancy  
25. * PSA screening for prostate cancer - An economic analysis  
26. * Cost-effectiveness of lumbar support for acute low back pain. A 
randomized controlled trial 
27. * Cost-effectiveness of rehabilitation following operative treatment of hip 
fracture  
28. * A model for prioritizing a Finnish sample patient population 
29. * Cost-effectiveness of the treatment for otitis media in children 
30. * Methods to measure the cost-effectiveness of secondary care  
International joint projects 
FinOHTA participates or has participated in the following international 
assessment projects. 
 
31. * Orthodontics, 2003–2006 
(SBU, Finnish Dental Association) 
32. * Sleep apnoea, 2004–2006 
(Nordic HTA units, University of Tampere, Finnish Lung Health Association) 
33. * IHI-QET: Internet Health Information - Aspects of quality, ethics and trust, 
2001–2004 
34. Hearing impairment, 2000–2003 
(Sweden, Norway, Denmark, UK) 
35. MedCERTAIN: Third-party evaluation of Internet health content, 2000–
2004 
(Finland, Germany, UK) 
36. Telemedicine: a systematic review, 2001, updated 2003 
(Finland, Canada, Australia) 
37. ECHTA/ECAHI: Health technology assessment in Europe, 2000–2002 
(15 European countries) 
38. AGREE: Assessing guidelines for research and evaluation, 1999–2004 
(14 European countries + Canada, New Zealand) 
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Cochrane projects 
As the national branch of the Nordic Cochrane Centre, FinOHTA has supported 
the following Cochrane projects. 
 
39. Psychodynamic psychotherapy in schizophrenia rehabilitation 
40. Effectiveness of psychoeducation  
41. Effectiveness of multiprofessional rehabilitation in musculo-sceletal diseases 
42. Prevention of caries with sealants 
43. Prevention of caries with fluoride varnish 
44. EU-PSI (Database of published and unpublished controlled clinical trials in 
psychiatry) 
Brief replies to questions 
The following list is a sample of the various questions that FinOHTA receives from 
different sources (e.g. the Ministry of Social Affairs and Health, hospital districts, 
municipalities, individuals). The questions have not led into actual research 
projects. Instead, FinOHTA has prepared an individual response to each question. 
 
• Cancer screening programs 
• Assessment of hearing among new-borns 
• Drug eluting stents 
• Gamma-knife 
• Effectiveness of complementary therapies 
• Provider-specific effectiveness of psychiatric treatments 
• Psychological debriefing 
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Project statistics 
During the period of January 1999 through June 2004, FinOHTA launched a total 
of 54 projects. During the same period, 46 projects were completed, 15 of which 
had been launched prior to year 1999. The number of project launched and 
completed each year is displayed in the following figure. 
 
Figure 1. Number of projects launched and completed 1999–2004(June) 
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Of the 54 projects that were launched during this period, the majority (36%) 
were systematic reviews. Every fourth project (24%) was a modelling study (e.g. 
modelling the costs of various treatment strategies) and 17% of the projects were 
primary research (e.g. randomized controlled trials). The remaining 23% or the 
projects used various other methods (e.g. expert panels, surveys). 
 
Figure 2. Project types 
Primary research
17 %
Modelling
24 %
Systematic review
36 %
Survey
6 %
Expert panel
4 %
Development
4 %
Methodology and Theory
7 %
Coordination
2 %
 
The Future of FinOHTA — an External Review 
 
 
 
 
 
 
 
40 
Project criteria 
The following criteria have been used while selecting project to be supported: 
 
• The method being assessed must be important for the health of the citizens 
and/or for the national economy, 
• The design of the study must be credible, 
• The study must be ethically acceptable, 
• The study must include the elements and goals of a good assessment 
project, 
• The methods used must be of high quality, 
• The results can be exploited in a concrete way, 
• The scientists performing the study must have enough experience to assess 
the topic, 
• The budget of the study must be realistic and the funding applied from 
FinOHTA must be reasonable compared to the whole budget, 
• The protocol must include a plan for the dissemination of results and 
follow-up of effects 
 
The criteria have been reviewed and refined during year 2004, and the following 
is a draft of the new criteria. 
 
FinOHTA supports assessment projects that study the effectiveness and cost-
effectiveness of health care technologies, as well as systematic literature reviews. 
The supported project may be part of a larger research project. Product 
development and purchase of equipment are not supported financially. 
The support is granted for a research group or organization. FinOHTA does not 
provide support in the form of tax-free scholarships and it does not directly hire 
research personnel. 
The assessment projects and literature reviews are evaluated with the help of the 
following questions: 
 
A. Topic and methods 
1. Is the problem significant from the viewpoint of public health or national 
economy? 
2. Is the selected research method appropriate to answer the research question? 
3. Does the proposed project contain sections and aims of a good assessment? 
• Does the project aim at assessing the effectiveness of the technology? 
• Does the project aim at assessing the cost-effectiveness of the technology? 
• Does the project address the social, ethical, juridical aspects, as well as 
quality of life? 
4. Is the research methodology of high quality? 
• In case of primary studies, is there a systematic review on the topic 
available? 
• Are sound scientific methods used? 
• Is the effectiveness research prospective, controlled and randomized? 
5. Can the results be utilized in practice? 
• Does the project aim at providing citizens with more health with health 
care resources? 
• Is the cost of the research reasonable in comparison with the knew 
knowledge attained? 
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• Can the results be used in other projects as better research methods or 
knowledge base? 
6. Are aspects relevant to ethics and privacy adequately addressed? 
• The applicant should also pay attention to the intellectual property rights of 
research results and possible products. 
7. Have the researchers declared any possible conflicts of interests? 
 
B. Researchers 
• Are the researchers qualified to study the topic? 
• Can the research group carry out the project? 
 
C. Funding 
• Is the funding in the right proportion with the aims? 
• Is the share suggested to be funded by FinOHTA in the right proportion 
taken into account the content of the project and its total funding? 
 
D. Timetable 
• Is the timetable realistic? 
 
E. Information dissemination, implementation and follow-up 
• Will the protocol of a randomized controlled trial be made public prior to 
or during the project? 
• How will the results be made public (final report and scientific publication) 
and how are the results communicated? 
• How is it ensured that the results will actually lead into a change in health 
care practice? 
• How can such a change be demonstrated? (e.g. surveys, register research, 
other methods) 
 
The Future of FinOHTA — an External Review 
 
 
 
 
 
 
 
42 
Appendix 4: Documentation used by the evaluation group 
The following documents are used in the external evaluation of FinOHTA. The 
abbreviation EED stands for External Evaluation Document. For referencing 
purposes the documents are coded in the following manner: 
A: General evaluation topics 
B: FinOHTA general topics 
C: FinOHTA communications 
D: FinOHTA research 
M: Minutes of evaluation meetings 
Actual evaluation documents 
• EED-A1: Work Plan 
• EED-A2: Evaluation Questions 
• EED-A3: Evaluation Documents (i.e. this document) 
• EED-A4: Interviews 
• EED-B1: FinOHTA Strategic Plan (Executive Summary) 
• EED-B2: Introduction to FinOHTA 
• EED-C1: FinOHTA Communication Plan (Executive Summary) 
• EED-C2: FinOHTA Communication Study (Executive Summary) 
• EED-D1: FinOHTA Projects 
• EED-M1: Minutes of the First Meeting 
• EED-M2: Minutes of the Second Meeting (including notes on interviews) 
• EED-M3: Minutes of the Third Meeting (including notes on further 
interviews) 
Auxiliary documents 
• FinOHTA Brochure (FinOHTA) 
• Samples of Newsletter Impakti (FinOHTA) 
• Table of Contents of the Quality handbook (FinOHTA) 
• Conflict of interest disclosure (FinOHTA) 
• Members of the Scientific Committee (FinOHTA) 
• Members of the Advisory Board (FinOHTA) 
• Evaluation of the Satakunta Macro Pilot Project, Executive Summary 
(FinOHTA) 
• Stakes international evaluation 1999. FinOHTA: actions from 
recommendations (FinOHTA) 
• Presentation: FinOHTA 1995–2004 (FinOHTA, Marjukka Mäkelä) 
• Journal article: 18 steps to Finnish health service reform (Euro Observer 
2002; 4(3): 3–4) 
• Report of the Working Group on Social Welfare and Health Care 
Information Reform 2005, Summary (Ministry of Social Affairs and Health, 
2003) 
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• Social and health policy-oriented research and development activities in 
Finland (Report by the Ministry of Social Affairs and Health, 2002). 
• STAKES Brochure: STAKES Today (STAKES) 
• STAKES Web Site printouts: Organisation structure, divisions and groups 
(STAKES) 
• Report: Jorma Rantanen et al. International evaluation of the National 
Research and Development Centre for Welfare and Health. Ministry of 
Social Affairs and Health Finland, Publications 1999:12 eng. 
• External evaluation of DACEHTA 2003. Sundhesstyrelsen 2003, Denmark. 
• Decision in Principle by the Council of State on securing the future of 
health care. Ministry of Social Affairs and Health. Brochures of the Ministry 
of Social Affairs and Health 2002:6 eng. 
• Lauri Nuutinen's survey on the views of hospital district directors in 2000 
(FinOHTA) 
• Research Programme on Health Services Research 2004–2007. Programme 
Memorandum. (Academy of Finland) 
• Sosiaali- ja terveysministeriön asetus lääkäri- ja hammaslääkärikoulutuksen 
sekä yliopistotasoisen terveystieteellisen tutkimustoiminnan korvauksen 
perusteista vuonna 2004. Asetus n:o 10, 2004. Social- och 
hälsovårdsministeriets förordning om grunderna för ersättning för läkar- och 
tandläkarutbildning samt hälsovetenskaplig forskning på universitetsnivå år 
2004. Förordning Nr 10, 2004. 
